NFE2L1 (Nuclear Factor Erythroid 2-Like 1), also known as Nrf1 (Nuclear factor erythroid 2-related factor 1), is a master transcriptional regulator of the antioxidant response and cellular proteostasis. As a member of the Cap'n'Collar (CNC) basic leucine zipper (bZIP) transcription factor family, NFE2L1 activates genes containing Antioxidant Response Elements (AREs) in their promoters, coordinating a comprehensive defense network against oxidative stress and maintaining protein homeostasis—processes critically implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington's disease. [1]
[^2]
[^3]
[^4]
[^5]
[^6]
[^7]
[^8]
[^9]
| Symbol | NFE2L1 |
|---|
| Full Name | Nuclear Factor Erythroid 2-Like 1 |
|---|
| Aliases | Nrf1, NFE2L1, TCF11, HEBP1 |
|---|
| Chromosomal Location | Chr17p13.3 |
|---|
| NCBI Gene ID | 4779 |
|---|
| Ensembl ID | ENSG00000100505 |
|---|
| UniProt ID | Q16186 |
|---|
| Protein Class | Transcription factor, bZIP family |
|---|
¶ Protein Structure and Function
The NFE2L1 protein contains several key structural domains: [2]
- N-terminal Transactivation Domain (TAD): Regulates transcriptional activity through interactions with coactivators
- Cap'n'Collar (CNC) Region: Basic DNA-binding domain that recognizes ARE sequences
- Leucine Zipper (Zip) Domain: Mediates dimerization with small Maf proteins
- Neh (Nrf2-ECH) Domains: Six conserved regulatory domains that interact with various signaling proteins
- C-terminal Regulatory Region: Contains a degron that controls protein stability
NFE2L1 functions as a transcriptional activator through the following mechanisms:
- DNA Binding: Forms heterodimers with small Maf proteins (MAFF, MAFG, MAFK) and binds to Antioxidant Response Elements (ARE) with the consensus sequence 5'-TGACnnnGC-3'
- Transcriptional Activation: Recruits coactivators including CBP/p300, BRG1, and various histone acetyltransferases
- Target Gene Activation: Regulates over 200 genes involved in antioxidant defense, xenobiotic metabolism, and proteostasis [3]
NFE2L1 activates genes encoding:
NFE2L1 is widely expressed throughout the central nervous system, with highest expression in: [4]
- Neurons: High expression in excitatory glutamatergic neurons and inhibitory GABAergic neurons
- Astrocytes: Moderate expression, increases in response to oxidative stress
- Microglia: Low baseline expression, strongly induced by neuroinflammation
- Oligodendrocytes: Moderate expression, important for myelin maintenance
NFE2L1 plays a complex role in Alzheimer's disease pathogenesis: [5]
- Amyloid-beta Toxicity: NFE2L1 activation protects against Aβ-induced oxidative stress and neuronal death. Studies show decreased NFE2L1 activity in AD brain tissue, contributing to vulnerability of neurons to oxidative damage.
- Tau Pathology: NFE2L1 regulates genes that influence tau phosphorylation and aggregation. Dysregulation of NFE2L1 may exacerbate tau pathology through impaired proteostasis.
- Neuroinflammation: NFE2L1 modulates microglial inflammatory responses. Its dysregulation contributes to chronic neuroinflammation in AD.
- Therapeutic Potential: Pharmacologic activation of NFE2L1 (e.g., with CDDO-Me, bardoxolone-methyl) represents a therapeutic strategy for AD to boost endogenous antioxidant defenses. [6]
In Parkinson's disease, NFE2L1 is critically involved in:
- Dopaminergic Neuron Protection: NFE2L1 activation protects ventral midbrain dopamine neurons from oxidative stress-induced death. The substantia nigra pars compacta has particularly high oxidative stress burden.
- Alpha-synuclein Pathogenesis: NFE2L1 regulates autophagy genes that clear α-synuclein aggregates. Impaired NFE2L1 function may contribute to Lewy body formation.
- Mitochondrial Dysfunction: NFE2L1 target genes include mitochondrial quality control regulators. Its dysfunction exacerbates mitochondrial deficits in PD.
- Neuroprotective Compounds: Sulforaphane and other NFE2L1 activators have shown promise in PD models. [7]
In ALS, NFE2L1 dysfunction contributes to disease pathogenesis: [8]
- Motor Neuron Vulnerability: NFE2L1 activity is reduced in ALS motor neurons, making them more susceptible to oxidative damage.
- Protein Aggregation: Impaired proteostasis due to NFE2L1 dysfunction may contribute to TDP-43 and SOD1 aggregation.
- Astrocyte Dysfunction: Astrocytic NFE2L1 dysregulation affects support functions for motor neurons.
- Therapeutic Implications: NFE2L1-activating compounds are being investigated for ALS treatment.
In Huntington's disease:
- Polyglutamine Toxicity: NFE2L1 activation counteracts oxidative stress induced by mutant huntingtin protein.
- Transcriptional Dysregulation: NFE2L1 function is impaired by mutant huntingtin through sequestration of transcription coactivators.
- Mitochondrial Protection: NFE2L1 target genes protect against mitochondrial dysfunction in HD.
- TDP-43 Pathology: NFE2L1 dysfunction may contribute to TDP-43 aggregation in FTD.
- Oxidative Stress: Increased oxidative stress in FTD brains associated with reduced NFE2L1 activity.
NFE2L1 activity is regulated by multiple signaling pathways:
- Oxidative Stress Sensing: Reactive oxygen species (ROS) oxidize cysteine residues on NFE2L1, altering its conformation and transcriptional activity.
- ER Stress Response: The unfolded protein response (UPR)))))))))) activates NFE2L1 through PERK and ATF6 signaling. [9]
- Kinase Signaling: MAPK/ERK, PI3K/Akt, and PKC pathways phosphorylate NFE2L1, modulating its activity.
- Proteasomal Regulation: NFE2L1 protein stability is regulated by the ubiquitin-proteasome system.
- Keap1-mediated degradation: While Keap1 primarily regulates NFE2L2, it can also sequester NFE2L1.
- Phosphorylation: GSK-3β phosphorylation can inhibit NFE2L1 transcriptional activity.
- Acetylation: p300-mediated acetylation can alter NFE2L1 DNA binding and stability.
Several compounds activate NFE2L1 and are being investigated for neurodegenerative diseases:
- CDDO-Me (Bardoxolone Methyl): Potent NFE2L1 activator, in clinical trials for diabetic kidney disease, being explored for AD/PD.
- Sulforaphane: Natural NFE2L1 activator from cruciferous vegetables, shown neuroprotective in animal models.
- Dimethyl fumarate (Tecfidera): FDA-approved for multiple sclerosis, activates NFE2L1 pathway.
- Oltipraz: Synthetic NFE2L1 activator investigated for neuroprotection.
- NFE2L1 Overexpression: Viral vector-mediated NFE2L1 delivery shows promise in preclinical models.
- Small Molecule Activators: Development of brain-penetrant NFE2L1 activators for neurodegenerative diseases.
- Combination Therapy: NFE2L1 activators combined with other neuroprotective strategies.
Key protein interactions include:
- KEAP1: Kelch-like ECH-associated protein 1, negative regulator.
- MAFF, MAFG, MAFK: Small Maf dimerization partners.
- CREBBP (CBP), EP300: Histone acetyltransferases/coactivators.
- BRG1: SWI/SNF chromatin remodeling complex.
- SUMO1: SUMOylation target, regulates nuclear localization.
- UBB (Ubiquitin): Proteasomal degradation.
- Nfe2l1-/- mice: Embryonic lethal, demonstrating essential developmental role.
- Conditional neuronal Nfe2l1 knockout: Show increased oxidative stress, progressive neurodegeneration.
- Astrocyte-specific Nfe2l1 knockout: Impaired neuroprotection, increased vulnerability to toxins.
- NFE2L1 overexpression: Protected against MPTP (PD model), Aβ toxicity (AD model), and SOD1G93A (ALS model).
- Human NFE2L1 knock-in: Improved antioxidant response and synaptic function in aging mice.